

Oklahoma Health Care Authority

Drug Utilization Review Board (DUR Board)

Meeting – February 8, 2017 @ 4:00 p.m.

Oklahoma Health Care Authority
4345 N. Lincoln Blvd.
Oklahoma City, Oklahoma 73105

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. Call to Order

- A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

2. Public Comment Forum

- A. Acknowledgement of Speakers for Public Comment

Items to be presented by Dr. Muchmore, Chairman:

3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A

- A. December 14, 2016 DUR Minutes – Vote
- B. December 14, 2016 DUR Recommendations Memorandum

Items to be presented by Dr. Abbott, Dr. Adams, Dr. Muchmore, Chairman:

4. Update on Medication Coverage Authorization Unit/SoonerPsych Program Update – See Appendix B

- A. Medication Coverage Activity for December 2016
- B. Pharmacy Help Desk Activity for December 2016
- C. Medication Coverage Activity for January 2017
- D. Pharmacy Help Desk Activity for January 2017
- E. SoonerPsych Program Update

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

5. Action Item – Vote to Prior Authorize Syndros™ (Dronabinol), Sustol® (Granisetron), and Bonjesta® (Doxylamine/Pyridoxine) – See Appendix C

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Ratterman, Dr. Muchmore, Chairman:

6. Action Item – Vote to Prior Authorize Viekira XR™ (Dasabuvir/Ombitasvir/Paritaprevir/Ritonavir) and Epclusa® (Sofosbuvir/Velpatasvir) – See Appendix D

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

7. Action Item – Vote to Prior Authorize Exondys 51™ (Eteplirsen) – See Appendix E

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

8. Action Item – Vote to Prior Authorize Otovel® (Ciprofloxacin/Fluocinolone Acetonide) – See Appendix F

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

9. Action Item – Vote to Prior Authorize Cinqair® (Reslizumab) and Bevespi Aerosphere® (Glycopyrrolate/Formoterol Fumarate) – See Appendix G

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Abbott, Dr. Muchmore, Chairman:

10. Action Item – Vote to Prior Authorize Fosrenol® (Lanthanum Carbonate), Velphoro® (Sucroferric Oxyhydroxide), and Auryxia™ (Ferric Citrate) – See Appendix H

- A. Introduction
- B. Phosphate Binder Product Comparison
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Abbott, Dr. Muchmore, Chairman:

11. Action Item – Vote to Prior Authorize Defitelio® (Defibrotide Sodium) – See Appendix I

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

12. Annual Review of Seizure Medications and 30-Day Notice to Prior Authorize Briviact® (Brivaracetam), Fycompa™ (Perampanel Oral Suspension), and Carnexiv™ (Carbamazepine Injection) – See Appendix J

- A. Current Prior Authorization Criteria
- B. Utilization of Seizure Medications
- C. Prior Authorization of Seizure Medications
- D. Market News and Updates
- E. Briviact® (Brivaracetam) Product Summary
- F. Fycompa™ (Perampanel Oral Suspension) Product Summary
- G. Carnexiv™ (Carbamazepine Injection) Product Summary
- H. College of Pharmacy Recommendations
- I. Utilization Details of Seizure Medications

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

13. Annual Review of Parkinson’s Disease Medications and 30-Day Notice to Prior Authorize Nuplazid™ (Pimavanserin) – See Appendix K

- A. Current Prior Authorization Criteria
- B. Utilization of Parkinson’s Disease Medications
- C. Prior Authorization of Parkinson’s Disease Medications
- D. Market News and Updates
- E. Nuplazid™ (Pimavanserin) Product Summary
- F. College of Pharmacy Recommendations
- G. Utilization Details of Parkinson’s Disease Medications

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

14. Annual Review of Hyperkalemia Medications and 30-Day Notice to Prior Authorize Veltassa® (Patiromer) – See Appendix L

- A. Chronic Hyperkalemia
- B. Utilization of Potassium Binders
- C. Market News and Updates
- D. Veltassa® (Patiromer) Product Summary
- E. College of Pharmacy Recommendations
- F. Utilization Details of Potassium Binders

Items to be presented by Dr. Abbott, Dr. Muchmore, Chairman:

15. 30-Day Notice to Prior Authorize Kanuma® (Sebelipase Alfa) – See Appendix M

- A. Lysosomal Acid Lipase Deficiency (LAL-D) Background Information
- B. Kanuma® (Sebelipase Alfa) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Abbott, Dr. Muchmore, Chairman:

16. Annual Review of Solaraze® (Diclofenac Sodium 3% Gel) and 30-Day Notice to Prior Authorize Picato® (Ingenol Mebutate 0.015% and 0.05% Gel) – See Appendix N

- A. Current Prior Authorization Criteria
- B. Utilization of Solaraze® (Diclofenac 3% Gel)
- C. Prior Authorization of Solaraze® (Diclofenac 3% Gel)
- D. Market News and Updates
- E. Picato® (Ingenol Mebutate Gel) Product Summary
- F. College of Pharmacy Recommendations

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

17. Annual Review of Anti-Migraine Medications and 30-Day Notice to Prior Authorize Onzetra® Xsail® (Sumatriptan Nasal Powder) and Zembrace™ SymTouch™ (Sumatriptan Injection) – See Appendix O

- A. Current Prior Authorization Criteria
- B. Utilization of Anti-Migraine Medications
- C. Prior Authorization of Anti-Migraine Medications
- D. Market News and Updates
- E. Onzetra® Xsail® (Sumatriptan Nasal Powder) Product Summary
- F. Zembrace™ SymTouch™ (Sumatriptan Injection) Product Summary
- G. College of Pharmacy Recommendations
- H. Utilization Details of Anti-Migraine Medications

Non-presentation; questions only:

18. Annual Review of Xuriden™ (Uridine Triacetate) – See Appendix P

- A. Hereditary Orotic Aciduria Overview
- B. Current Prior Authorization Criteria
- C. Utilization of Xuriden™ (Uridine Triacetate)
- D. Prior Authorization of Xuriden™ (Uridine Triacetate)
- E. Market News and Updates
- F. College of Pharmacy Recommendations

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman:

19. FDA and DEA Updates – See Appendix Q

Items to be presented by Dr. Abbott, Dr. Muchmore, Chairman:

20. Future Business* (Upcoming Product and Class Reviews)

- A. Multiple Sclerosis Medications
- B. Zinplava™ (Bezlotoxumab)
- C. Pulmonary Arterial Hypertension Medications
- D. Ulcerative Colitis and Crohn's Disease Medications
- E. Naloxone Medications
- F. Gaucher Disease Medications
- G. Makena® (Hydroxyprogesterone Caproate) and Vaginal Progesterone Products

**Future business subject to change.*

21. Adjournment